Probiotics in the prevention and management of human diseases: Probiotics in the prevention and management of irritable bowel syndrome

Onderzoeksoutput: Chapterpeer review

68 Downloads (Pure)


Children with irritable bowel syndrome (IBS) suffer chronic abdominal pain related to defecation. Alterations in the composition of the gastrointestinal microbiome are involved in the different pathophysiological mechanisms. The number of randomized controlled trials on gastrointestinal tract microbiome manipulation in children with IBS is limited. Moreover, there are major heterogeneities in study designs such as differences in inclusion criteria, including patients with different pain-related functional gastrointestinal disorders and differences primary outcomes. Most studies are underpowered. Many studies are performed in Asian countries, where the gastrointestinal microbiome may differ from other parts of the world. More reviews on the topic are published than original research data. Since adverse events or harm have not been reported, and since there is: (1) some positive literature and (2) no evidence for another effective treatment, one could consider to administer probiotics because it cannot be excluded that administration of selected probiotic products may result in some benefit and is at the same time unlikely to cause harm, following the concept of “primum not nocere.” One should then look for those products available on the market for which there are some data on efficacy available. However, there is insufficient evidence to recommend manipulation of the gastrointestinal tract composition with interventions such as administration of probiotics, despite the evidence that dysbiosis seems a constant associated pathophysiologic factor.
Originele taal-2English
TitelProbiotics in the prevention and management of human diseases
RedacteurenMitesh Kumar Dwivedi, N Amaresan, A Sankaranarayanan, E. Helen Kemp
Aantal pagina's6
StatusPublished - 2022

Citeer dit